Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
Invest New Drugs
; 39(4): 1081-1088, 2021 08.
Article
en En
| MEDLINE
| ID: mdl-33660194
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Piridinas
/
Quinolonas
/
Mesotelioma
/
Antineoplásicos
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2021
Tipo del documento:
Article